Swiss Carbogen Amcis, a pharmaceutical process development and Active Pharmaceutical Ingredient (API) manufacturing company, has advised its employees and the authorities today of its plans for restructuring the Swiss company's operations in Bubendorf (BL), Aarau (AG) and Hunzenschwil (Neuland, AG).

The company finds itself forced to take this step on the grounds of the inadequate profitability brought about by the strong Swiss franc and the delayed effects of the financial crisis. The company currently has approximately 350 employees in Switzerland.

The planned restructuring of the leading pharmaceutical services company will allow the Aarau site to focus more strongly on development and the Hunzenschwil (Neuland) site on the pilot production of early phase projects.

Large-volume production and the manufacturing of highly active agents will continue at the Bubendorf site.

This concentration of the areas of responsibility will mean that approximately 60 persons will need to be made redundant. Carbogen Amcis is strengthening man power in the Hunzenschwil (Neuland) site to innovatively meet customer demand further on. As far as possible, employees will be offered equivalent positions in Switzerland.

"During the transition we will direct our focus, as we would in any case, towards attending to customer demand and providing our customers with consistently high service," said Jay R. Vyas, managing director of the Dishman Group, owner of Carbogen Amcis.

"The restructuring allows Carbogen Amcis to be prepared for the future as a sustainably successful organization. The restructured company will have potential for growth and the ability to adapt itself to a changing market situation."